These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 35791876)

  • 1. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
    Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
    Fitzgerald T; Zhdanava M; Pilon D; Shah A; Hilts A; Lefebvre P; Feldman SR
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):1053-1068. PubMed ID: 36929120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.
    Li Y; Lu JJ; Zhong XY; Yu YY; Yu N; Wang Y; Yi XM; Ding YF; Shi YL
    Clin Cosmet Investig Dermatol; 2022; 15():2245-2252. PubMed ID: 36304759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
    Graier T; Salmhofer W; Jonak C; Weger W; Kölli C; Gruber B; Sator PG; Prillinger K; Mlynek A; Schütz-Bergmayr M; Richter L; Ratzinger G; Painsi C; Selhofer S; Häring N; Wippel-Slupetzky K; Skvara H; Trattner H; Tanew A; Inzinger M; Tatarski R; Bangert C; Ellersdorfer C; Lichem R; Gruber-Wackernagel A; Hofer A; Legat F; Schmiedberger E; Strohal R; Lange-Asschenfeldt B; Schmuth M; Vujic I; Hoetzenecker W; Trautinger F; Saxinger W; Müllegger R; Quehenberger F; Wolf P
    Br J Dermatol; 2021 Jun; 184(6):1094-1105. PubMed ID: 33289075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
    Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
    Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
    Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 15. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center.
    Jung SW; Lim SH; Jeon JJ; Heo YW; Choi MS; Hong SP
    Biomedicines; 2022 May; 10(5):. PubMed ID: 35625795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia.
    Sullivan J; Hannam S; Puig A; Maranta D; McGeachie AB; Baker C
    Australas J Dermatol; 2023 Nov; 64(4):504-513. PubMed ID: 37705180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival in patients with psoriasis is associated with the availability of biologic medications.
    Shalom G; Cohen AD; Feldhamer I; Comaneshter D; Freud T; Pavlovsky L
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1524-1528. PubMed ID: 31953883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.